Inhibitor challenges in the paediatric setting
- 5 January 2006
- journal article
- Published by Wiley in Haemophilia
- Vol. 12 (1) , 106-107
- https://doi.org/10.1111/j.1365-2516.2006.01165.x
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activityJournal of Thrombosis and Haemostasis, 2004
- Prevention of bleeds in hemophilia patients with inhibitors: Emerging data and clinical directionAmerican Journal of Hematology, 2004
- FEIBA® safety profile in multiple modes of clinical and home‐therapy applicationHaemophilia, 2004
- Safety of factor VIII inhibitor bypass activity (FEIBA®): 10‐year compilation of thrombotic adverse eventsHaemophilia, 2002
- The Treatment of Bleeding in Hemophilic Patients with Inhibitors with Recombinant Factor VIIaSeminars in Thrombosis and Hemostasis, 2000
- Treatment options for bleeding episodes in patients undergoing immune tolerance therapyHaemophilia, 1999
- Use of prothrombin complex concentrates and activated prothrombin complex concentrates as prophylactic therapy in haemophilia patients with inhibitorsHaemophilia, 1999
- Multicenter Retrospective Study on the Utilization of FEIBA in France in Patients with Factor VIII and Factor IX InhibitorsThrombosis and Haemostasis, 1997
- MASSIVE FACTOR-VIII INFUSION IN HÆMOPHILIAC WITH FACTOR-VIII INHIBITOR, HIGH RESPONDERThe Lancet, 1977